Feng, Li; Yu, Shujia; Wang, Hai; Yang, Shengwei; Li, Xue; Dai, Hongjuan; Zhao, Liwen; Jiang, Cheng; Wang, Yazhou published the artcile< Synthesis and biological evaluation of spirocyclic chromane derivatives as a potential treatment of prostate cancer>, Category: quinuclidine, the main research area is spirocyclic chromane preparation antitumor prostate cancer; HAT inhibitors; antitumor activity; p300/CBP.
Herein, new compounds from the lead compound A-485 were designed using mol. dynamic simulations. A series of new spirocyclic chroman derivatives was prepared, characterized and proven to be a potential treatment of prostate cancer. The most potent compound I inhibited the proliferation of enzalutamide-resistant 22Rv1 cells with an IC50 value of 96 nM. Furthermore, one of diastereomers of the compound I displayed favorable overall pharmacokinetic profiles, and better tumor growth inhibition than A-485 in an in vivo xenograft model.
Molecules published new progress about Antitumor agents. 120570-05-0 belongs to class quinuclidine, and the molecular formula is C7H14N2, Category: quinuclidine.
Referemce:
Quinuclidine – Wikipedia,
Quinuclidine | C7H13N | ChemSpider